Soy isoflavone genistein in prevention and treatment of prostate cancer.
Dietary habits and incidence of prostate cancer (PCa) are very different in several parts of the world. Among the differences between Eastern and Western diets is the greater intake of soy in the Eastern cultures. This might be one factor contributing to a lower incidence of PCa in Asian men. Many studies using PCa cells and animal studies of chemical carcinogenesis have shown that a wide range of dietary compounds have cancer chemopreventive potential. Therefore, the interest in nutrition-based approaches for prevention and treatment of PCa is increasing. We reviewed all experimental preclinical in vitro and in vivo data as well as clinical trials performed with soy isoflavone genistein for prevention and treatment of PCa. The preclinical data for genistein presented in this review show a remarkable efficacy against PCa cells in vitro with molecular targets ranging from cell cycle regulation to induction of apoptosis. In addition, seemingly well-conducted animal experiments support the belief that genistein might have a clinical activity in human cancer therapy. However, it is difficult to make definite statements or conclusions on clinical efficacy of genistein because of the great variability and differences of the study designs, small patient numbers, short treatment duration and lack of a standardized drug formulation. Although some results from these genistein studies seem encouraging, reliable or long-term data on tumor recurrence, disease progression and survival are unknown. The presented data potentially allow recommending patients the use of genistein as in soy products in a preventive setting. However, at present there is no convincing clinical proof or evidence that genistein might be useful in PCa therapy.
Perabo
F G E
FG
Department of Urology, University Hospital, Bonn, Germany. perabo@lycos.com
Von Löw
E C
EC
Ellinger
J
J
von Rücker
A
A
Müller
S C
SC
Bastian
P J
PJ
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D019833:Genistein / Q000627:therapeutic use*; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013025:Glycine max / Q000737:chemistry*
D016588:Anticarcinogenic Agents; D007529:Isoflavones; D019833:Genistein